Immunooncology Market Slated to Bring in US$ 27,846.3 Mn by End of 2017-2025

Owing to higher efficiency as compared to conventional therapies such as radiation, chemo and surgery, doctors around the globe are increasingly prescribing immunotherapy to cancer patients. Immuno-oncology therapies have low toxicity, making it easier for the patients to undergo such treatment procedures. Increasing clinical approval of immunotherapy drugs continues to support speedy adoption of immuno-oncology treatments while higher investments to further improve immunotherapies is anticipated to create greater market opportunities for drug makers. Persistence Market Research (PMR) is its latest report projects that the global market for immune-oncology is set to witness a CAGR of 16.5% between 2016 and 2025, to reach a valuation of US$ 27,846.3 Mn by the end of the forecast period.
Request For Report Sample@ https://www.persistencemarketresearch.com/samples/11329
Collaborative efforts and initiatives to identify therapies for difficult-to-treat illnesses is a key factor driving the overall immune-oncology market. However, high drug pricing, development costs and limited technical expertise are some of the challenges likely to dampen the surging spirit of the market over 2025.
Demand for Immune Checkpoint Inhibitors to Remain Robust
Currently, immune checkpoint inhibitor therapy is widely used for treating several carcinogenic disorders. Immune checkpoint inhibitor drugs help the body fight against certain proteins that are normally used by various tumors to suppress immune responses. Sales revenue from immune checkpoint inhibitors drugs is anticipated to reach US$ 7,321.7 Mn by 2017-end. Of late, a number immune checkpoint inhibitor drugs have been approved by the US FDA including Yervoy (anti-CTLA-4), Opdivo and Keytruda (anti-PD1) and Tecentriq (anti-PD-L1). Demand for these drugs is expected to further gain traction, owing to a significant investment by biopharmaceutical companies in developing a robust pipeline. Meanwhile, immune system modulator is the second most preferred immune-oncology therapy and is expected to create an incremental opportunity of US$ 659.9 Mn between 2017 and 2025. Two major approved drugs that fall in this category include interferons and interleukins.
Request For Report Table of Content (TOC)@ https://www.persistencemarketresearch.com/methodology/11329
Based on therapeutic area, demand for immune-oncology therapeutics for melanoma will remain high throughout the forecast period. By end user, hospitals account for the largest revenue share of the market and are expected to represent around US$ 5,557.1 Mn by 2017-end.
Amongst regions, the immuno-oncology market in North America accounted for a revenue share of around 67.1% in 2016. The region’s market is expected to witness a strong CAGR of 17.1% during the assessment period and retain its top position. In terms of revenue, the US dominates the North America immuno-oncology market and is projected to continue to do so in 2017 and beyond owing to the presence of prominent drug manufacturing companies in the country.
Competitive Landscape
PMR is its report has profiled some of the leading companies operating in the global immuno-oncology market, which includes Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb, Dendreon Corporation, F.Hoffmann-La Roche, Merck & Co., Inc. Novartis AG, Pfizer, Inc., Sanofi. In terms of revenue share, Bristol-Myers Squibb (BMS) was ranked at the top in 2016, thanks to the success of its blockbuster products Opdivo and Yervoy.
Know More About Report@ https://www.persistencemarketresearch.com/mediarelease/immunooncology-market.asp

Collaborative Robot (Cobot) Market Insights Deep Analysis 2022-2030

With the advancements in technology, robotics is becoming available at a price that suits the pockets of even smaller as well as bigger companies. All thanks to the development of low-cost components, which have paved way for the upsurge of the collaborative robots or cobots .Collaborative robots are intended to collaborate with humans at work sites, and hence making automation a trouble-free job for businesses of all sizes. By now, cobots have been seen as a game-changer for a wide variety of applications. W hy cobots over traditional robots? The new robotics technology is outdoing the weighty, daunting robots usually locked in the cages for security reasons. Now, it’s time to make use of cobots in those heavy industrial tasks! These robots are quite affordable, safe, and flexible to deploy. They are programmed to work in collaboration with humans and not under humans—unlike traditional robots. With these advanced-automated robots, you can forget the cages and make ...

Intraoperative Neuromonitoring Market Revenue to Record Stellar Growth Rate

According to Intraoperative Neuromonitoring Market Analysis by Research Dive, the global market forecast will be $3,413.0 million by the end of 2026 , at a 4.5% CAGR , growing from $2,400.0 million in the end of 2018 . Intraoperative Neuromonitoring Market Drivers: Growing aged populace globally, along with increasing occurrence of chronic illnesses, are the major driving aspects for the intraoperative neuromonitoring market growth. Furthermore, intraoperative monitoring is an important process that assists in risk management throughout complex surgeries. This factor is projected to propel the market size in the coming years. Furthermore, rising trend of medical tourism along with growing investments for healthcare infrastructure in developing economies are projected to create significant revenue generating opportunities in the global market. Nevertheless, shortage of trained workforce for the control and maintenance of intraoperative neur...

2-ethylhexyl Caprate Market to Incur Meteoric Growth During 2018-2026

Introduction: 2-Ethylhexyl Caprate Market 2-ethylhexyl caprate , also known as 2-ethylhexyl decanoate, is an organic chemical compound with the molecular formula C18H32O2. In the manufacturing of 2-ethylhexyl caprate, ethyl reacts with hexyl in the presence of caproic acid as a catalyst to form 2-ethylhexyl caproic acid, which on further treatment with esterification process forms a mixture of 2-ethylhexyl caprate crude. This mixture of 2-ethylhexyl caprate crude is distilled to obtain pure 2-ethylhexyl caprate. 2-ethylhexyl caprate finds several applications in chemical, pharmaceutical and textile industries as a reagent, catalyst and excipient. Along with this, 2-ethylhexyl caprate is used in the manufacturing of elastomers and coatings. On the basis of safety, 2-ethylhexyl caprate is the least harmful in the available caprate group and has low vapor pressure, which can reduce hazards while handling as compared to other caprates, such as ethylhexyl palmitate and oth...

Industrial Research World

Search This Blog